
Claims

1. Use of Compound I or a pharmaceutically acceptable salt thereof



Compound I

in the manufacture of a medicament for the prevention and/or treatment of a lung injury in a subject diagnosed with or suffering from a respiratory infection, wherein the lung injury is a consequence of the infection and wherein the lung injury comprises damage to the respiratory tissue.

2. The use according to claim 1, wherein the infection is viral, bacterial, fungal, or parasitic.

3. The use according to any one of the preceding claims, wherein the respiratory infection is a viral infection.

4. The use according to any one of the preceding claims, wherein the lung injury is damage to the respiratory tissue selected from any one or combination of damage to the bronchi, bronchioles, alveoli, and tissues or cellular structures associated therewith; or is selected from alveolar damage and pulmonary or alveolar infiltration.

5. The use according to any one of the preceding claims, wherein the lung injury is acute hypoxic respiratory insufficiency or failure, acute lung injury (ALI) or acute respiratory distress syndrome (ARDS).

6. The use according to any one of the preceding claims, wherein the medicament is to be used for preventing the development, or the progression of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) in the subject suffering from a respiratory infection.

7. The use according to any one of the preceding claims, wherein the respiratory infection is a respiratory viral infection caused by a respiratory virus selected from an influenza virus, a rhinovirus, a respiratory syncytial virus, an adenovirus, a coronavirus (CoV), a dengue virus, or a parainfluenza virus.

8. The use according to claim 7, wherein the viral respiratory infection is caused by a coronavirus, and optionally wherein the coronavirus is a SARS-CoV, SARS-CoV2, or MERS-CoV.

9. The use according to claim 8, wherein the respiratory infection is COVID-19.

10. The use according to any one of claims 1 to 2, or any one of claims 4 to 6, wherein the respiratory infection is a respiratory bacterial infection caused by a gram-negative and/or a gram-positive bacteria, further optionally wherein the bacteria is a pseudomonas bacteria (e.g. pseudomonas aeruginosa), a klebsiella bacteria (e.g. klebsiella pneumoniae), a haemophilius bacteria (e.g. haemophilius influenzae), a streptococcus bacteria (e.g. streptococcus pneumoniae), a staphylococcus bacteria (e.g. staphylococcus aureus), or legionella bacteria (e.g. legionella pneumophila).

11. The use according to any one of the preceding claims wherein the medicament is to be administered to a subject in need thereof before, simultaneously with, and/or after a treatment with oxygen support or mechanical ventilation.

12. The use according to any one of the preceding claims wherein the subject is receiving a second active ingredient, e.g. a corticosteroid such as dexamethasone.

13. The use according to claim 12 wherein the medicament is to be used for preventing the development, or the progression of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS).

14. The use according to any one of claims 12 or 13, wherein the medicament is packaged with written instructions for the administration of Compound I to a subject receiving the second active ingredient, wherein the instructions indicate a sequential, or simultaneous administration of the medicament and the second active ingredient.

15. The use according to any one of the preceding claims, wherein the medicament is to be administered or is adapted for administration to a human subject.

16. The use according to any one of the preceding claims, wherein the medicament is to be administered by injection or infusion, inhalation, or by oral administration.

17. The use according to any one of the preceding claims, wherein the medicament comprises at least one unit dose of Compound I or a pharmaceutically acceptable salt thereof, wherein the unit dose is between about 0.005 to 20 mg/kg.